<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30158936</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1664-3224</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in immunology</Title>                <ISOAbbreviation>Front Immunol</ISOAbbreviation>            </Journal>            <ArticleTitle>Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response.</ArticleTitle>            <Pagination>                <MedlinePgn>1894</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2018.01894</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">The histamine receptor 2 antagonist ranitidine is a commonly used, non-prescription, medication. It limits the development, growth, and metastasis of breast cancers in mouse models of disease. In this study, we examined the role of B cells in this response, the impact of ranitidine on the development of antitumor antibodies and subpopulations of natural killer cells using murine breast cancer models.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Peripheral blood granulocyte populations were assessed in both E0771-GFP and 4T1 orthotopic tumor-bearing mice by evaluation of stained blood smears. Antibody responses were assessed both in terms of the levels of anti-GFP antibodies detected by enzyme-linked immunosorbent assay and also by antibody binding to the surface of tumor cells evaluated by flow cytometry. B cell and NK cell populations were examined in the draining lymph nodes and spleens of tumor-bearing animals, by flow cytometry with and without ranitidine treatment.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Oral ranitidine treatment was not associated with changes in peripheral blood granulocyte populations in tumor-bearing mice. However, ranitidine treatment was associated with the development of enhanced antitumor antibody responses. This was not limited to the tumor setting since ranitidine-treated mice immunized with ovalbumin also demonstrated increased IgG antibody responses. Analysis of B cell populations indicated that while B1 cell populations remained unchanged there was a significant decrease in B2 cells in the tumor-draining inguinal lymph nodes. Notably, ranitidine did not significantly inhibit primary tumor growth in B cell-deficient animals. Examination of NK cell populations revealed a significant decrease in the proportion of intermediately functionally mature NK cells populations (CD27<sup>+</sup>CD11b<sup>-</sup>) in ranitidine-treated tumor-bearing mice compared with untreated tumor-bearing controls.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">These data demonstrate an important role for B cells in the enhanced antitumor immune response that occurs in response to ranitidine treatment. Our findings are consistent with a model, whereby ranitidine reduces tumor-associated immune suppression allowing for the development of more effective antitumor responses mediated by B cells which may include the participation of NK cells. These data underline the importance of considering widely used histamine receptor antagonists as modulators of antitumor immunity to breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rogers</LastName>                    <ForeName>Dakota</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Dalhousie Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vila-Leahey</LastName>                    <ForeName>Ava</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Dalhousie Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pess√¥a</LastName>                    <ForeName>Ana Clara</ForeName>                    <Initials>AC</Initials>                    <AffiliationInfo>                        <Affiliation>Dalhousie Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oldford</LastName>                    <ForeName>Sharon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Dalhousie Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marignani</LastName>                    <ForeName>Paola A</ForeName>                    <Initials>PA</Initials>                    <AffiliationInfo>                        <Affiliation>Department Biochemistry and Molecular Biology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marshall</LastName>                    <ForeName>Jean S</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Dalhousie Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Immunol</MedlineTA>            <NlmUniqueID>101560960</NlmUniqueID>            <ISSNLinking>1664-3224</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Allergy Clin Immunol. 2013 Jul;132(1):194-204</RefSource>                <PMID Version="1">23465664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Biosci (Landmark Ed). 2012 Jan 01;17:40-53</RefSource>                <PMID Version="1">22201731</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 2010 Feb 15;184(4):2116-23</RefSource>                <PMID Version="1">20083654</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013;8(2):e56567</RefSource>                <PMID Version="1">23451056</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Dermatol Sci. 2016 Aug;83(2):106-15</RefSource>                <PMID Version="1">27155791</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2016 Oct 1;76(19):5696-5706</RefSource>                <PMID Version="1">27503932</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2008 Aug 1;372(3):491-6</RefSource>                <PMID Version="1">18502198</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunol Allergy Clin North Am. 2006 May;26(2):245-59, vii</RefSource>                <PMID Version="1">16701143</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Leukoc Biol. 2014 Jul;96(1):151-9</RefSource>                <PMID Version="1">24610880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Rev. 2008 Jan;29(1):12-23; quiz 24</RefSource>                <PMID Version="1">18166617</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2001 Sep 27;413(6854):420-5</RefSource>                <PMID Version="1">11574888</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2</RefSource>                <PMID Version="1">18432775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Invest Dermatol. 2008 Jul;128(7):1615-6</RefSource>                <PMID Version="1">18548077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hepatology. 2009 Sep;50(3):799-807</RefSource>                <PMID Version="1">19551844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Allergy Clin Immunol. 2011 Apr;127(4):943-53.e1-10</RefSource>                <PMID Version="1">21269673</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Cancer. 2017 Sep;3(9):615-620</RefSource>                <PMID Version="1">28867165</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 1988 Apr;108(4):566-7</RefSource>                <PMID Version="1">3348565</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chem Immunol Allergy. 2006;91:174-87</RefSource>                <PMID Version="1">16354958</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Immunol. 2017 Oct;48:108-113</RefSource>                <PMID Version="1">28923468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 2007 Dec 1;179(11):7907-15</RefSource>                <PMID Version="1">18025238</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Immunology. 2012 May;136(1):103-14</RefSource>                <PMID Version="1">22304689</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 2009 Apr 15;182(8):4499-506</RefSource>                <PMID Version="1">19342621</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncoimmunology. 2016 Mar 10;5(7):e1151591</RefSource>                <PMID Version="1">27622015</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jul 19;7(29):46466-46481</RefSource>                <PMID Version="1">27341131</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol Res. 2017;2017:8282391</RefSource>                <PMID Version="1">28265583</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Mar 8;7(10):10891-904</RefSource>                <PMID Version="1">26863636</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Allergy Clin Immunol. 2011 Dec;128(6):1153-62</RefSource>                <PMID Version="1">21824648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Immunol Immunopathol. 1994 Oct;73(1):96-102</RefSource>                <PMID Version="1">7923922</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Jun 15;21(12):2861-9</RefSource>                <PMID Version="1">26078432</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Allergy. 2017 Dec;72(12):1925-1935</RefSource>                <PMID Version="1">28618071</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Immunol. 2017 Nov 13;8:1544</RefSource>                <PMID Version="1">29181007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2016 Oct 1;76(19):5597-5601</RefSource>                <PMID Version="1">27634765</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">histamine receptor</Keyword>            <Keyword MajorTopicYN="N">immunology</Keyword>            <Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword>            <Keyword MajorTopicYN="N">natural killer cells</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30158936</ArticleId>            <ArticleId IdType="doi">10.3389/fimmu.2018.01894</ArticleId>            <ArticleId IdType="pmc">PMC6104125</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>